Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...